Interferon‐α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo‐controlled trial
Harry L. A. Janssen, Luuk Berk, Rudolf A. Heijtink, Fiebo J. W. Ten Kate, Solko W. Schalm – 1 March 1993 – Interferon‐α therapy leads to HBeAg seroconversion in only one third of patients with chronic hepatitis B. In an attempt to increase the seroconversion rate, we investigated the combination of interferon‐α and zidovudine in a subset of patients with presumably low response rates for interferon‐α monotherapy.